Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke
NCT06137300Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of Human urinary kallidinogenase in ischemic stroke (2 arms). Primary endpoint: Proportion of patients with Modified Rankin Scale Score 0-2 at 90 days. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
Human urinary kallidinogenase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06137300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137300.